Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $572.41 | 10 | 100.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| ABBVIE INC. | $381.32 | 5 | $0 (2024) |
| Janssen Pharmaceuticals, Inc | $86.10 | 2 | $0 (2022) |
| Merck Sharp & Dohme LLC | $74.43 | 2 | $0 (2024) |
| GENZYME CORPORATION | $30.56 | 1 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $145.98 | 2 | ABBVIE INC. ($121.10) |
| 2023 | $235.31 | 5 | ABBVIE INC. ($155.20) |
| 2022 | $159.70 | 2 | ABBVIE INC. ($105.02) |
| 2020 | $31.42 | 1 | Janssen Pharmaceuticals, Inc ($31.42) |
All Payment Transactions
10 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 09/01/2024 | Merck Sharp & Dohme LLC | VAXNEUVANCE (Biological) | Food and Beverage | In-kind items and services | $24.88 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 03/22/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $121.10 | General |
| Category: NEUROSCIENCE | ||||||
| 11/10/2023 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $11.31 | General |
| Category: NEUROSCIENCE | ||||||
| 09/03/2023 | GENZYME CORPORATION | — | Food and Beverage | In-kind items and services | $30.56 | General |
| 09/02/2023 | Merck Sharp & Dohme LLC | VAXNEUVANCE (Biological) | Food and Beverage | In-kind items and services | $49.55 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 06/14/2023 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $18.73 | General |
| Category: NEUROSCIENCE | ||||||
| 04/28/2023 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $125.16 | General |
| Category: NEUROSCIENCE | ||||||
| 10/06/2022 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $105.02 | General |
| Category: NEUROSCIENCE | ||||||
| 03/10/2022 | Janssen Pharmaceuticals, Inc | INVEGA (Drug) | Food and Beverage | In-kind items and services | $54.68 | General |
| Category: Neuroscience | ||||||
| 11/18/2020 | Janssen Pharmaceuticals, Inc | INVEGA SUSTENNA (Drug) | Food and Beverage | In-kind items and services | $31.42 | General |
| Category: Neuroscience | ||||||
About Dr. Cesar Padilla, MD
Dr. Cesar Padilla, MD is a Mental Health healthcare provider based in Camuy, Puerto Rico. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 03/14/2006. The National Provider Identifier (NPI) number assigned to this provider is 1205804325.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Cesar Padilla, MD has received a total of $572.41 in payments from pharmaceutical and medical device companies, with $145.98 received in 2024. These payments were reported across 10 transactions from 4 companies. The most common payment nature is "Food and Beverage" ($572.41).
Practice Information
- Specialty Mental Health
- Location Camuy, PR
- Active Since 03/14/2006
- Last Updated 07/08/2007
- Taxonomy Code 101YM0800X
- Entity Type Individual
- NPI Number 1205804325
Products in Payments
- VRAYLAR (Drug) $381.32
- VAXNEUVANCE (Biological) $74.43
- INVEGA (Drug) $54.68
- INVEGA SUSTENNA (Drug) $31.42
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.